Computational design of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-Targeted Oncolytic Virus Therapy to In-hibit Angiogenesis in Non-Small Cell Lung Cancer
This study computationally identifies a high-affinity VEGFR2-binding Fab and models its integration into an engineered oncolytic virus to block angiogenesis and enhance targeted therapy for Non-Small Cell Lung Cancer.
Posted by buchanle on Friday, June 12th, 2026 in May 2026, Non-Small Cell Lung Cancer, Oncolytic Cancer, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
In Silico Screening of BiTE Molecule Targeting CD22 and T-Cell Receptor Complex for Acute Lymphoblastic Leukemia
This research presents a fully in silico pipeline for engineering a Bispecific T-Cell Engager by identifying and validating scFv antibodies that target CD22 and the T-cell receptor for acute lymphoblastic leukemia therapy.
Posted by buchanle on Wednesday, June 3rd, 2026 in May 2026, Acute Lymphoblastic Leukemia, Bispecific T-Cell Engager, Cancer Cell Hypoxia, CD22 Receptor, T-Cell Receptor
Molecular and Computational Characterization of GLP-1 Receptor–Agonist Binding Mechanisms for Rational Therapeutic Design
This research paper presents a computational pipeline that identifies key GLP-1 Receptor binding determinants and proposes improved liraglutide variants for next-generation weight-management therapies.
Posted by buchanle on Tuesday, June 2nd, 2026 in May 2026, AlphaFold, GLP-1 Receptor, Liraglutide, Weight Management
Computational Simulations of Bispecific Aptamers Targeting CD16+ Natural Killer Cells and PD-L1+ Cancer Cells
A computational study exploring the design of bispecific aptamers to enhance NK cell-mediated cancer therapy through targeted receptor interactions.
Posted by buchanle on Friday, June 20th, 2025 in May 2025, Aptamer, CAR T-cell Therapy, Molecular Docking, NK Cells
Computation simulations of IL-13Rα2 receptor+ CAR T-cell targeting high-grade glioma
This work uses computer simulations to investigate the interactions between CAR T-cells expressing CD45 and CD62 receptors and the IL-13Rα2 receptor, offering insights into the best way to target high-grade gliomas using CAR T-cell therapy.
Posted by buchanle on Thursday, June 19th, 2025 in May 2025, CAR T-cell Therapy, Glioma, Molecular Docking, Molecular Dynamics